Pricing of Oversubscribed USD 110 Million Financing of Oculis Holding AG
Oculis Holding AG (Nasdaq: OCS; XICE: OCS), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, announced the pricing of...
RetinAI acquired by EssilorLuxottica
EssilorLuxottica, a global leader in vision care and eyewear, has acquired Ikerian AG, a health technology company operating under the RetinAI brand, specializing in AI and data management in eyecare.
Nuclidium AG closes Series B financing round
NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, announced the successful closing of its Series B financing round, raising CHF 79m (EUR 84m).
Mosanna Therapeutics raises USD 80m in Series-A-Funding
Mosanna Therapeutics AG closed its USD 80m Series A funding round.
GlycoEra AG closes Series-B-financing round
GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, announced the closing of an oversubscribed USD 130m Series-B-financing.
Aktiia Secures USD 42m Series-B-Funding to Expand into New Markets
Aktiia, a blood pressure intelligence platform, has completed an oversubscribed USD 42m Series-B funding-round, bringing the company's total funding to date to USD 100m.
BioVersys completes its IPO at SIX Swiss Exchange
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, has completed its Initial Public at the SIX Swiss Exchange.
VISCHER advises Kelun-Biotech, Harbour BioMed and RTW Investments in USD 200m Series A Financing of Windward Bio
Windward Bio Group AG, a Basel-based private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, announced its launch with a USD 200m series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners.
Ikerian closes Series B Financing with strategic partnership
Ikerian, a healthcare software platform company that organizes multimodal data at-scale, closes the first tranche of USD 8m Series B Financing to advance its AI platform alongside.
Mininavident AG acquired by global dental leader Straumann Group
Mininavident AG, in Liestal, developer and manufacturer of the world’s smallest dynamic navigation system for dental implant placement, was acquired by the Straumann Group, a global leader in tooth replacement, orthodontic solutions and adjacent dental technologies.